RDHL (RDHL) Stock Price & Analysis
RDHL (RDHL) fell 11.36% to USD 0.63 as of July 25, 2026 at 07:28 UTC, according to Nexqual real-time market data.
RDHL last closed at USD 0.71; the session ranged USD 0.63–0.7 on volume of 20,219 shares. Market capitalization is $3.85M, with a 52-week range of USD 0.63–2.79 (NCM). Source: Nexqual, July 25, 2026 at 07:28 UTC.
Key Statistics (as of July 25, 2026 at 07:28 UTC)
| Price | USD 0.63 |
|---|---|
| Change | ▼ 11.36% (down) |
| Previous Close | USD 0.71 |
| Open | USD 0.69 |
| Day Range | USD 0.63 – 0.7 |
| 52-Week Range | USD 0.63 – 2.79 |
| Volume | 20,219 shares |
| Market Cap | $3.85M |
| Exchange | NCM |
Technical Analysis (RDHL)
Nexqual's technical model rates RDHL "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:28 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.33 (oversold) |
| vs SMA50 | Below (USD 0.86) |
| MACD | -0.05 (negative) |
Analyst Ratings (RDHL)
Wall Street analysts rate RDHL "None", per Nexqual as of July 25, 2026 at 07:28 UTC.
| Consensus Rating | None |
|---|
Earnings (RDHL)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2022-12-31 | USD 0 vs est 0 ▲ beat |
| 2022-09-30 | USD -60 vs est -10 ▼ miss |
| 2022-06-30 | USD -20 vs est -10 ▼ miss |
| 2022-03-31 | USD -30 vs est -30 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
Financials & Fundamentals (RDHL)
| Total Revenue | $286,000 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -2765.38% |
| Profit Margin | -150.00% |
| Debt / Equity | 25.07 |
| Current Ratio | 0.34 |
| Total Cash | $3.97M |
| Total Debt | $1.07M |
| Free Cash Flow | $-2.18M |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
Financial Health Score (RDHL)
Nexqual rates RDHL's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 07:28 UTC.
| Growth | Critical — Revenue -28% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $4M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Mixed — No data |
Ownership (RDHL)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +8.53% |
| Shares Outstanding | 6.08M |
| Float | 4.20M |
| Short % of Float | +0.33% |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
Leadership (RDHL)
RDHL is led by Dror Ben-Asher (age 59), Co-Founder, Chairman & CEO, per Nexqual as of July 25, 2026 at 07:28 UTC.
| Co-Founder, Chairman & CEO | Dror Ben-Asher (age 59) |
|---|---|
| Chief Financial Officer | Razi Ingber (age 41) |
| Chief Operating Officer | Gilead Raday MPhil, MSc (age 50) |
| Chief Commercial Officer & Director | Rick D. Scruggs (age 65) |
| Chief Scientific Officer | Mark L. Levitt |
Major Backers & Investors (RDHL)
Notable institutional backers of RDHL include Yorkville Advisors Global, LP, Gagnon Securities, LLC, Citadel, according to Nexqual as of July 25, 2026 at 07:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Yorkville Advisors Global, LP | 5.77% |
| Gagnon Securities, LLC | 1.45% |
| Citadel | 0.34% |
| Xtx Topco Ltd | 0.25% |
| Stonex Group Inc. | 0.24% |
| Two Sigma Securities, LLC | 0.21% |
| Gamma Investing LLC | 0.11% |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMDA | Kamada Ltd. | USD 7.06 | ▲ 0.71% |
| BLRX | BioLineRx Ltd. | USD 2.82 | ▼ 1.05% |
| GLMD | Galmed Pharmaceuticals Ltd. | USD 0.51 | ▲ 1.56% |
| KALA | KALA BIO, Inc. | USD 0.63 | ▼ 13.95% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.52 | ▼ 10.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:28 UTC. This page is informational and not investment advice.